MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


Allergy Therapeutics secures cash to see it through September

ALN

Allergy Therapeutics PLC shares fell on Tuesday, despite securing an additional £5 million in loans, extending its cash runway.

Allergy Therapeutics is a Sussex, England-based biotechnology company which specialises in allergy vaccines.

Its shares were down 14% to 4.01 pence each in London on Tuesday morning. In the past 12 months, the shares have shot up from 1.31p.

Major shareholders SkyGem Acquisition Ltd and Southern Fox Investments Ltd have agreed to provide a further £5 million from an existing loan facility. The facility was first announced in December last year.

Allergy Therapeutics said it now has extended its cash runway into late September.

It noted that there remains a further £12.5 million of uncommitted funding available under the amended loan facility, and it ‘continues to explore further funding options to support its ongoing operations and development pipeline’.

Copyright 2024 Alliance News Ltd. All Rights Reserved.